Pharming Group Receives Positive EU CHMP Opinion for Joenja (leniolisib) for APDS Treatment

summarizeSummary

Pharming Group received a positive CHMP opinion for Joenja® (leniolisib) for APDS, positioning it to become the first approved treatment for the rare immunodeficiency in the European Union.

check_boxKey Events

• Positive CHMP Opinion for Joenja®

  The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for Joenja® (leniolisib) for Activated Phosphoinositide 3-kinase delta Syndrome (APDS) in adult and pediatric patients 12 years and older.

• Potential First-in-Class EU Treatment

  If approved, Joenja® would become the first approved treatment in the European Union for APDS, a rare primary immunodeficiency, addressing a significant unmet medical need.

• Final EU Decision Expected Soon

  A final decision by the European Commission on the marketing authorization for Joenja® is expected within approximately two months (Q2 2026), which would validate the centralized marketing authorization across 27 EU Member States, Norway, Iceland, and Liechtenstein.

• Builds on Recent Global Approvals

  This positive opinion follows the recent regulatory approval of Joenja® in Japan earlier this week, demonstrating strong global progress for the drug.

auto_awesomeAnalysis

Pharming Group has achieved a critical regulatory milestone with a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for Joenja® (leniolisib). This recommendation is a significant step towards marketing authorization in the European Union for the treatment of Activated Phosphoinositide 3-kinase delta Syndrome (APDS), a rare primary immunodeficiency. If approved, Joenja would be the first targeted treatment for APDS in the EU, addressing a substantial unmet medical need. This positive development follows recent regulatory approval in Japan, indicating strong global progress for the drug. The final decision from the European Commission is anticipated within approximately two months, which would unlock a new major market for the company.